Evidence map›Paper›PMID 35629268›Full record

ReviewJournal of personalized medicine2022

Personalized Management of Patients with Chronic Rhinosinusitis with Nasal Polyps in Clinical Practice: A Multidisciplinary Consensus Statement.

Eugenio De Corso, Maria Beatrice Bilò, Andrea Matucci, Veronica Seccia, Fulvio Braido, Matteo Gelardi, Enrico Heffler, Manuela Latorre, Luca Malvezzi, Girolamo Pelaia and 3 more

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07616609 (A Randomized, Placebo-Controlled, Double-Blinded Trial of Preoperative Stapokibart With Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps), which is not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07616609 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Randomized, Placebo-Controlled, Double-Blinded Trial of Preoperative Stapokibart With Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps

TypeinterventionalSponsorBeijing Tongren HospitalRan2026 to 2028Enrolled48ConditionsChronic Rhinosinusitis With Nasal Polyps (CRSwNP)ArmsStapokibart, Matched placebo
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Optimising care for chronic rhinosinusitis with nasal polyps and asthma in multimorbid patients: a multidisciplinary Delphi consensus.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Blood and local nasal eosinophilia in chronic rhinosinusitis with nasal polyps: prevalence and correlation with severity of disease.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2025
    Article
  12. Review
  13. The Effects ofBiomedicines · 2024
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Practical recommendations for managing severe chronic rhinosinusitis with nasal polyps in the era of biologics.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 1 country.

Eugenio De CorsoA. Gemelli University Hospital Foundation IRCCS, Otorhinolaryngology, Catholic University of the Sacred Heart, 00168 Rome, Italy.ORCID 0000-0001-5761-7018
Maria Beatrice BilòDepartment of Clinical and Molecular Sciences, Università Politecnica delle Marche, 60131 Ancona, Italy.
Andrea MatucciImmunoallergology Unit, University Hospital Careggi, 50134 Florence, Italy.
Veronica SecciaOtolaryngology Audiology and Phoniatric Operative Unit, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa, 56124 Pisa, Italy.ORCID 0000-0002-6297-8034
Fulvio BraidoRespiratory Unit for Continuity of Care, IRCCS, Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Matteo GelardiDepartment of Otolaryngology, University Hospital of Foggia, 71100 Foggia, Italy.ORCID 0000-0003-4406-0008
Enrico HefflerPersonalized Medicine, Asthma and Allergy-IRCCS Humanitas Research Hospital, 20122 Milan, Italy.ORCID 0000-0002-0492-5663
Manuela LatorreDepartment of Medical Specialties, Pulmonary Unit, Hospital of Massa, 54100 Massa, Italy.
Luca MalvezziDepartment of Biomedical Sciences, Humanitas University, 20072 Milan, Italy.ORCID 0000-0002-5385-9818
Girolamo PelaiaDepartment of Health Sciences, University Magna Graecia, 88100 Catanzaro, Italy.ORCID 0000-0001-9288-8913
Gianenrico SennaDepartment of Allergology, Azienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy.
Paolo CastelnuovoDepartment of Biotechnology and Life Sciences, Università degli Studi dell'Insubria, 21100 Varese, Italy.
Giorgio Walter CanonicaPersonalized Medicine, Asthma and Allergy-IRCCS Humanitas Research Hospital, 20122 Milan, Italy.
Humanitas University · ITAzienda Ospedaliera Universitaria Integrata Verona · ITAzienda Ospedaliero-Universitaria Careggi · ITMagna Graecia University · ITMarche Polytechnic University · ITOspedale Policlinico San Martino · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Foggia · ITUniversity of Insubria · ITUniversity of Pisa · IT

Funding

Novartis (Italy) not applicable
6 · The paper itself

Abstract

Chronic rhinosinusitis (CRS) is a sino-nasal chronic inflammatory disease, occurring in 5-15% of the general population. CRS with nasal polyps (CRSwNP) is present in up to 30% of the CRS population. One-third of CRSwNP patients suffer from disease that is uncontrolled by current standards of care. Biologics are an emerging treatment option for patients with severe uncontrolled CRSwNP, but their positioning in the treatment algorithm is under discussion. Effective endotyping of CRSwNP patients who could benefit from biologics treatment is required, as suggested by international guidelines. Other issues affecting management include comorbidities, such as allergy, non-steroidal anti-inflammatory drug-exacerbated respiratory disease, and asthma. Therefore, the choice of treatment in CRSwNP patients depends on many factors. A multidisciplinary approach may improve CRSwNP management in patients with comorbidities, but currently there is no shared management model. We summarize the outcomes of a Delphi process involving a multidisciplinary panel of otolaryngologists, pulmonologists, and allergist-immunologists involved in the management of CRSwNP, who attempted to reach consensus on key statements relating to the diagnosis, endotyping, classification and management (including the place of biologics) of CRSwNP patients.

Indexed as

allergyasthmabiologicschronic rhinosinusitishypersensitivitynasal polypsnon-steroidal anti-inflammatory drugstype 2 inflammation

Identifiers

PMID35629268
PMCPMC9143504
OpenAlexW4282917627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.